What is it about?
Lung cancer (LC) is the leading cause of cancer-related death globally. Hypoxia in cancer is linked with malignancy, and its phenotype is implicated in the hypoxic reaction, which is being studied as a prospective cancer treatment target.
Featured Image
Why is it important?
Lung cancer (LC) is the leading cause of cancer-related death globally. Comprehensive knowledge of the cellular and molecular etiology of LC is perilous for the development of active treatment approaches. Hypoxia in cancer is linked with malignancy, and its phenotype is implicated in the hypoxic reaction, which is being studied as a prospective cancer treatment target. The hypervascularization of the tumor is the main feature of human LC, and hypoxia is a major stimulator of neo-angiogenesis. It was seen that low oxygen levels in human LC are a critical aspect of this lethal illness. However, as there is a considerable body of literature espousing the presumed functional relevance of hypoxia in LC, the direct measurement of oxygen concentration in Human LC is yet to be determined. This narrative review aims to show the importance and as a future target for novel research studies that can lead to the perception of LC therapy in hypoxic malignancies.
Perspectives
Read the Original
This page is a summary of: Hypoxia A Typical Target in Human Lung Cancer Therapy, Current Protein and Peptide Science, June 2024, Bentham Science Publishers,
DOI: 10.2174/0113892037252820231114045234.
You can read the full text:
Contributors
The following have contributed to this page